Your browser doesn't support javascript.
loading
Maternal and neonatal outcomes after gonadotropin-releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization.
Budinetz, Tara H; Mann, Jessica S; Griffin, Daniel W; Benadiva, Claudio A; Nulsen, John C; Engmann, Lawrence L.
Afiliación
  • Budinetz TH; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Center for Advanced Reproductive Services, University of Connecticut Health Center, Farmington, Connecticut.
  • Mann JS; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Center for Advanced Reproductive Services, University of Connecticut Health Center, Farmington, Connecticut.
  • Griffin DW; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Center for Advanced Reproductive Services, University of Connecticut Health Center, Farmington, Connecticut.
  • Benadiva CA; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Center for Advanced Reproductive Services, University of Connecticut Health Center, Farmington, Connecticut.
  • Nulsen JC; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Center for Advanced Reproductive Services, University of Connecticut Health Center, Farmington, Connecticut.
  • Engmann LL; Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Center for Advanced Reproductive Services, University of Connecticut Health Center, Farmington, Connecticut. Electronic address: lengmann@uchc.edu.
Fertil Steril ; 102(3): 753-8, 2014 Sep.
Article en En | MEDLINE | ID: mdl-24954776
OBJECTIVE: To compare the rate of congenital anomalies, obstetrical complications, and neonatal complications in antagonist cycles where either GnRH agonist (GnRHa) or hCG was used for final oocyte maturation. DESIGN: Retrospective cohort study. SETTING: University-based tertiary fertility center. PATIENT(S): Three hundred ninety-two women under 40 years of age who underwent controlled ovarian stimulation using a GnRH antagonist protocol and who had final oocyte maturation triggered with either a GnRHa or hCG that resulted in pregnancy and delivery after 16 weeks' gestation. INTERVENTION(S): GnRHa versus hCG trigger of final oocyte maturation. MAIN OUTCOME MEASURE(S): Congenital anomaly rates, obstetrical complications, and neonatal complications. RESULT(S): There were no significant differences in the rate of congenital anomalies between GnRHa and hCG trigger (6.6 vs. 9.2%). There were also no differences in the maternal complications (27.6 vs. 20.8%) or neonatal complications (19.7 vs. 20.0%) between the GnRHa trigger and hCG trigger groups. CONCLUSION(S): GnRHa trigger does not affect the rate of congenital anomalies or obstetrical or neonatal complications and remains a viable option in the prevention of ovarian hyperstimulation syndrome.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inducción de la Ovulación / Resultado del Embarazo / Fertilización In Vitro / Hormona Liberadora de Gonadotropina / Fármacos para la Fertilidad Femenina Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Newborn / Pregnancy Idioma: En Revista: Fertil Steril Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inducción de la Ovulación / Resultado del Embarazo / Fertilización In Vitro / Hormona Liberadora de Gonadotropina / Fármacos para la Fertilidad Femenina Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Newborn / Pregnancy Idioma: En Revista: Fertil Steril Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos